Our aim was to investigate the effect of CYP2D6 activity and additional systemic treatment, including chemotherapy, GnRH-analogs and switch to aromatase inhibitors, on MD change, in a cohort of tamoxifen-treated pre- and postmenopausal breast cancer patients. Here, CYP19A1 is linked to breast cancer.